Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Azilsartan Medoxomil Tablets in Healthy Chinese Volunteers
NCT07881263Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan medoxomil in hypertension (HTN) (4 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum observed plasma concentration up to 48 hours, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration up to 48 hours and 1 more. Started Sep 2024; status: completed.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07881263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881263.